Dicot Pharma
Research Dicot Pharma (DICOT.ST) on Bullrun: market cap SEK 724.26M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerDICOT.ST
- ExchangeSSME
- CountrySweden
- SectorHealthcare
- IndustryDrug Manufacturers - Specialty & Generic
- CurrencySEK
- Market capSEK 724.26M
- Financial periodQ1 2026
- RevenueSEK 0
- Net income-SEK 14.80M
- Free cash flow-SEK 12.80M
Valuation Snapshot
latest market cap is SEK 724.26M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | n/a | n/a | n/a | n/a | -0.04 | SEK 69.19M | n/a | SEK 73.36M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-15 | SEK 724.26M | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 SEK.
About Dicot Pharma
Dicot Pharma AB engages in the development of pharmaceutical products in Sweden. It develops LIB-01 that is in Phase 2a clinical trial for the treatment of erectile dysfunction and under medical discovery for treating premature ejaculation. The company was formerly known as Dicot AB (publ) and changed its name to Dicot Pharma AB in May 2024. Dicot Pharma AB was incorporated in 2015 and is based in Uppsala, Sweden.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Dicot Pharma's market cap?
Dicot Pharma's market capitalization is SEK 724.26M.
What does Dicot Pharma do?
Dicot Pharma AB engages in the development of pharmaceutical products in Sweden. It develops LIB-01 that is in Phase 2a clinical trial for the treatment of erectile dysfunction and under medical discovery for treating premature ejaculation. The company was formerly known as Dicot AB (publ) and changed its name to Dicot Pharma AB in May 2024. Dicot Pharma AB was incorporated in 2015 and is based in Uppsala, Sweden.